2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 2.543 | 4.972 | 7.838 | 8.551 | 6.920 | 927 | 0 | 0 | 0 | 0 |
Total Income - EUR | 2.543 | 4.972 | 7.838 | 8.551 | 6.920 | 927 | 0 | 0 | 0 | 0 |
Total Expenses - EUR | 0 | 11 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit/Loss - EUR | 2.543 | 4.960 | 7.822 | 8.551 | 6.920 | 927 | 0 | 0 | 0 | 0 |
Net Profit/Loss - EUR | 2.467 | 4.811 | 7.651 | 8.294 | 6.712 | 899 | 0 | 0 | 0 | 0 |
Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Evysmed Srl
See the company's note based on the submitted financial data, relative to the industry of which it is a part.
Check Financial Rating2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Current Assets | 11.115 | 16.038 | 23.104 | 31.130 | 37.192 | 37.399 | 36.690 | 35.876 | 35.988 | 35.878 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Receivables | 820 | 0 | -713 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash | 10.294 | 16.038 | 23.816 | 31.130 | 37.192 | 37.399 | 36.690 | 35.876 | 35.988 | 35.878 |
Shareholders Funds | 10.706 | 15.607 | 23.098 | 31.002 | 37.145 | 37.325 | 36.617 | 35.805 | 35.916 | 35.807 |
Social Capital | 45 | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 |
Debts | 409 | 431 | 6 | 128 | 47 | 74 | 73 | 71 | 71 | 71 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "8621 - 8621" | |||||||||
CAEN Financial Year | 8621 |
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Reports that can be accessed based on the subscription:
Get the contact details for any company and get in touch with it.